STEEN Solution™ was used for the first time to give localized delivery of a chemotherapy agent to a patient suffering from metastatic lung sarcoma through In-Vivo Lung Perfusion (IVLP) . This was also the first time STEEN Solution was used to perfuse a lung on In-Vivo i.e. on a living patient. The aim of the study is to prove safety and evaluate the ability to use STEEN Solution™ to improve isolated tissue therapy. read more
“This number will increase to 69 million by the end of 2030. Arthritis has been identified as one of the most common causes of disability in the world today.”
This research report titled ‘Global Extremity Products Market 2016-2020’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes an up to date analysis and forecasts for various market segments and all geographical regions.
Fear Factor: Study Shows a New Genetic Candidate for Treating PTSD | EON: Enhanced Online News
Compugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology Program IND filing for COM701 anticipated next year